Related Experiment Video
Updated: Jun 3, 2026
Murine Cervical Aortic Transplantation Model using a Modified Non-Suture Cuff Technique
Published on: November 2, 2019
Cardiac allograft vasculopathy: current knowledge and future direction
Monica Colvin-Adams1, Adheesh Agnihotri
1University of Minnesota, Minneapolis, MN, USA. colvi005@umn.edu
Insights
Cardiac allograft vasculopathy (CAV) is a major cause of death after heart transplantation. Understanding its risk factors, pathogenesis, and early diagnosis using methods like intravascular ultrasound (IVUS) is crucial for improving patient outcomes.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Cardiac allograft vasculopathy (CAV) is a significant cause of late mortality in heart transplant recipients.
- Despite improvements in transplant survival, CAV remains a critical clinical challenge.
- It represents a unique form of accelerated coronary artery disease in the transplanted heart.
Purpose of the Study:
- To review the multifaceted risk factors contributing to CAV development.
- To elucidate the complex pathogenesis involving immunological and non-immunological pathways.
- To discuss current and emerging diagnostic strategies for early CAV detection.
Main Methods:
- Review of existing literature on CAV risk factors, pathogenesis, and diagnosis.
- Analysis of traditional (dyslipidemia, diabetes, hypertension) and non-traditional (CMV infection, HLA mismatch, rejection) risk factors.
- Evaluation of diagnostic modalities including intravascular ultrasound (IVUS), angiography, echocardiography, CT, and MRI.
Main Results:
- CAV results from a complex interplay of factors leading to endothelial injury and intimal proliferation.
- Risk factors encompass traditional cardiovascular elements and transplant-specific immunological challenges.
- Intravascular ultrasound (IVUS) is highlighted as a valuable prognostic tool, though angiography remains a benchmark.
Conclusions:
- Early diagnosis of CAV is essential due to asymptomatic presentation in denervated hearts.
- A comprehensive understanding of risk factors and pathogenesis is key to managing CAV.
- Advancements in diagnostic techniques, particularly IVUS, aid in patient management and prognosis assessment.
Abstract:
Cardiac allograft vasculopathy (CAV) is a unique form of coronary artery disease affecting heart transplant recipients. Although prognosis of heart transplant recipients has improved over time, CAV remains a significant cause of mortality beyond the first year of cardiac transplantation. Many traditional and non-traditional risk factors for the development of CAV have been described. Traditional risk factors include dyslipidemia, diabetes and hypertension. Non-traditional risk factors include cytomegalovirus infection, HLA mismatch, antibody-mediated rejection, and mode of donor brain death. There is a complex interplay between immunological and non-immunological factors ultimately leading to endothelial injury and exaggerated repair response. Pathologically, CAV manifests as fibroelastic proliferation of intima and luminal stenosis. Early diagnosis is paramount as heart transplant recipients are frequently asymptomatic owing to cardiac denervation related to the transplant surgery. Intravascular ultrasound (IVUS) offers many advantages over conventional angiography and is an excellent predictor of prognosis in heart transplant recipients. Many non-invasive diagnostic tests including dobutamine stress echocardiography, CT angiography, and MRI are available; though, none has replaced angiography. This review discusses the risk factors, pathogenesis, and diagnosis of CAV and highlights some current concepts and recent developments in this field.
